Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
Bariatric surgery
Inflammation
Metabolic syndrome
Non-alcoholic fatty liver disease
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
20
9
2018
medline:
11
1
2020
entrez:
20
9
2018
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD), driven by the obesity epidemic, has become the most common form of liver disease. Despite this, there is controversy regarding the prevalence and severity of NAFLD in obesity. Obesity-related factors, such as increasing adiposity, metabolic disease and inflammation, may influence prevalence. We therefore prospectively measured NAFLD prevalence in obesity and studied factors associated with NAFLD. We recruited consecutive bariatric patients. Intraoperative liver biopsies were taken. The liver, adipose tissue and serum were collected to measure inflammation. Adipocyte cell size was measured. NAFLD severity was correlated to body mass index (BMI), metabolic health and adipose characteristics. There were 216 participants; BMI 45.9 ± 8.9 kg/m NAFLD remains endemic in obesity; however, NASH/steatofibrosis are less common than previously reported. Worsening obesity and metabolic disease increase odds of NAFLD independently, with substantially compounded effect with both. These observations may help with risk stratification in obese populations. We were unable to delineate clear associations between adipose inflammation and NASH/steatofibrosis in this obese population. Australian Clinical Trials Registry ( ACTRN12615000875505 ).
Sections du résumé
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD), driven by the obesity epidemic, has become the most common form of liver disease. Despite this, there is controversy regarding the prevalence and severity of NAFLD in obesity. Obesity-related factors, such as increasing adiposity, metabolic disease and inflammation, may influence prevalence. We therefore prospectively measured NAFLD prevalence in obesity and studied factors associated with NAFLD.
MATERIALS AND METHODS
We recruited consecutive bariatric patients. Intraoperative liver biopsies were taken. The liver, adipose tissue and serum were collected to measure inflammation. Adipocyte cell size was measured. NAFLD severity was correlated to body mass index (BMI), metabolic health and adipose characteristics.
RESULTS
There were 216 participants; BMI 45.9 ± 8.9 kg/m
CONCLUSION
NAFLD remains endemic in obesity; however, NASH/steatofibrosis are less common than previously reported. Worsening obesity and metabolic disease increase odds of NAFLD independently, with substantially compounded effect with both. These observations may help with risk stratification in obese populations. We were unable to delineate clear associations between adipose inflammation and NASH/steatofibrosis in this obese population.
TRIAL REGISTRATION
Australian Clinical Trials Registry ( ACTRN12615000875505 ).
Identifiants
pubmed: 30229460
doi: 10.1007/s11695-018-3479-2
pii: 10.1007/s11695-018-3479-2
doi:
Banques de données
ANZCTR
['ACTRN12615000875505']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-108Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Obesity (Silver Spring). 2009 Mar;17(3):601-5
pubmed: 19238145
Hepatology. 2011 Mar;53(3):810-20
pubmed: 21319198
Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6
pubmed: 25917783
Obes Rev. 2018 Feb;19(2):281-294
pubmed: 29119725
Annu Rev Pathol. 2016 May 23;11:451-96
pubmed: 26980160
Endocr Rev. 2013 Feb;34(1):84-129
pubmed: 23238855
Gastroenterology. 2015 Sep;149(3):635-48.e14
pubmed: 26028579
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):23-8
pubmed: 21634051
Ann Med. 2011 Dec;43(8):617-49
pubmed: 21039302
Obes Surg. 2001 Jun;11(3):254-7
pubmed: 11433896
Ann Hepatol. 2009;8 Suppl 1:S4-8
pubmed: 19381118
J Hepatol. 2009 Aug;51(2):354-62
pubmed: 19464069
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Hepatology. 2010 Feb;51(2):679-89
pubmed: 20041406
Arch Intern Med. 2008 Aug 11;168(15):1609-16
pubmed: 18695074
Front Endocrinol (Lausanne). 2013 May 10;4:52
pubmed: 23675368
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Hepatol. 2012 May;56(5):1152-8
pubmed: 22245892
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Arch Surg. 2003 Nov;138(11):1240-4
pubmed: 14609874
Hepatol Commun. 2017 Jun 06;1(5):421-428
pubmed: 29404470
Gut. 2017 Sep;66(9):1688-1696
pubmed: 27884920
Eur Heart J. 2013 Feb;34(5):389-97
pubmed: 22947612
Semin Liver Dis. 2014 Feb;34(1):98-107
pubmed: 24782263
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Obes Surg. 2003 Jun;13(3):347-9
pubmed: 12841891
Diabetes. 2006 Jun;55(6):1554-61
pubmed: 16731817
Rev Endocr Metab Disord. 2013 Sep;14(3):219-27
pubmed: 23928851
Anesthesiology. 2008 May;108(5):812-21
pubmed: 18431116
Gastroenterology. 1999 Jun;116(6):1413-9
pubmed: 10348825
Metabolism. 2001 Dec;50(12):1499-504
pubmed: 11735101
Cell. 2014 Jan 16;156(1-2):20-44
pubmed: 24439368
Aliment Pharmacol Ther. 2012 Sep;36(6):560-8
pubmed: 22817613